1. Scope of the Invention
The present invention relates to an apparatus permitting the treatment of bodily conduits, typically blood vessels, in an area of a bifurcation, e.g. in an area where a principal conduit separates into two secondary conduits. It also relates to equipment for positioning this apparatus.
2. Description of the Related Art
It is known to treat narrowing of a rectilinear blood vessel by means of a radially expandable tubular device, commonly referred to as a stent. This stent is introduced in the unexpanded state into the internal lumen of the vessel, in particular by the percutaneous route, as far as the area of narrowing. Once in place, the stent is expanded in such a way as to support the vessel wall and thus re-establish the appropriate cross section of the vessel.
Stent devices can be made of a non-elastic material, in which case the stent is expanded by an inflatable balloon on which it is engaged. Alternatively, the stent can be self-expanding, e.g. made of an elastic material. A self-expanding stent typically expands spontaneously when withdrawn from a sheath which holds it in a contracted state.
For example, U.S. Pat. Nos. 4,733,065 and 4,806,062 illustrate existing stent devices and corresponding positioning techniques.
A conventional stent is not entirely suitable for the treatment of a narrowing situated in the area of a bifurcation, since its engagement both in the principal conduit and in one of the secondary conduits can cause immediate or delayed occlusion of the other secondary conduit.
It is known to reinforce a vascular bifurcation by means of a stent comprising first and second elements, each formed by helical winding of a metal filament. The first of the two elements has a first part having a diameter corresponding to the diameter of the principal vessel, and a second part having a diameter corresponding to the diameter of a first one of the secondary vessels. The first element is intended to be engaged in the principal vessel and the second element is intended to be engaged in the first secondary vessel. The second element has a diameter corresponding to the diameter of the second secondary vessel. After the first element has been put into place, the second element is then coupled to the first element by engaging one or more of its turns in the turns of the first element.
This equipment permits reinforcement of the bifurcation but appears unsuitable for treating a vascular narrowing or an occlusive lesion, in view of its structure and of the low possibility of radial expansion of its two constituent elements.
Moreover, the shape of the first element does not correspond to the shape of a bifurcation, which has a widened transitional zone between the end of the principal vessel and the ends of the secondary vessels. Thus, this equipment does not make it possible to fully support this wall or to treat a dissection in the area of this wall. Additionally, the separate positioning of these two elements is quite difficult.
There is provided in accordance with one aspect of the present invention, a method of deploying first and second stents in the vicinity of a vascular bifurcation of a main vessel into a first and a second branch vessels. The method comprises the steps of providing a delivery catheter having first and second stents thereon. The catheter is positioned such that the first and second stents are in the vicinity of the bifurcation. The first stent is deployed in a branch vessel, and the second stent is deployed in the main vessel. The second stent expands to a first diameter at a proximal end and a second, greater diameter at a distal end.
In one implementation of the invention, the deploying step includes inflating a balloon within at least one of the stents. The deploying step may additionally or alternatively comprise the step of permitting at least one of the stents to self expand.
In accordance with another aspect of the present invention, there is provided a deployment system for treating a bifurcation of a main vessel and a first and second branch vessels. The deployment system comprises an elongate flexible body, having a proximal end and a distal end, and a first stent and a second stent carried by the distal end. A restraint is provided for releasably restraining the stents on the flexible body. The first stent has different dimensions in an unconstrained expanded configuration than the second stent.
Preferably, a guidewire lumen extends axially through at least a portion of the flexible body. The guidewire lumen has a proximal access port and a distal access port. In one embodiment, the proximal access port is positioned along the flexible body, spaced distally apart from the proximal end. Alternatively, the proximal access port is positioned at the proximal end of the flexible body.
In one embodiment, the releasable restraint comprises an axially moveable control element extending along the length of the flexible body. The control element may be connected to a tubular sheath, which is axially moveably carried by the distal end of the flexible body. Alternatively, the releasable restraint may comprise a dissolvable media.
In one embodiment, only one of the first and second stents expands into a substantially cylindrical configuration in an unconstrained expansion.
In accordance with a further aspect of the present invention, there is provided a method of treating a vascular bifurcation of a main vessel into first and second branch vessels. The method comprises the steps of deploying a substantially cylindrical stent in a first branch vessel, and deploying a tapered stent in the main vessel. Both the substantially cylindrical stent and the tapered stent are deployed from the same catheter. Preferably, at least one of the substantially cylindrical stent and the tapered stent is deployed from a delivery catheter by axially displacing an outer sheath on the delivery catheter. In one embodiment, the tapered stent has a relatively smaller diameter first end and a relatively larger diameter second end, and the cylindrical stent is positioned adjacent the second end.
In accordance with another aspect of the present invention, there is provided a stent deployment catheter. The catheter comprises an elongate flexible tubular body, having a proximal end and a distal end. A first and second stent are carried by the distal end. A handpiece is provided on the proximal end. A control is provided on the handpiece, having a first position for indicating partial deployment of the first stent, and a second position indicating complete deployment of the first stent. Preferably, the control further comprises a third position, indicating partial deployment of the second stent. The control preferably also includes a fourth position, indicating complete deployment of the second stent.
In accordance with a further aspect of the present invention, there is provided a method of treating a bifurcation of a main vessel into first and second branch vessels. The method comprises the steps of providing a catheter, having a first and a second stent thereon. The catheter is positioned in the vicinity of the bifurcation, and a first stent is partially deployed into the first branch vessel. Contrast media is introduced to permit visualization of the location of the first stent, and the first stent is thereafter completely deployed into the first branch. The method additionally comprises the step of partially deploying the second stent in the main vessel. Contrast media may be introduced to permit visualization of the partially deployed second stent in the main vessel. The second stent may thereafter be completely deployed in the main vessel.
All of these embodiments are intended to be within the scope of the present invention herein disclosed. These and other embodiments of the present invention will become readily apparent to those skilled in the art from the following detailed description of the preferred embodiments having reference to the attached figures, the invention not being limited to any particular embodiment(s) disclosed.
Having thus summarized the general nature of the invention, certain preferred embodiments and modifications thereof will become apparent to those skilled in the art from the detailed description herein having reference to the attached figures, of which:
As described above, the attached Figures illustrate a stent system and corresponding delivery system for use in treating vessels (e.g. conduits) within the human body at areas of bifurcations.
According to the illustrated embodiment, the stents 12, 14 generally comprise an expandable mesh structure which includes a plurality of mesh cells 36. The mesh cells 36 of these segments are in one embodiment elongated in the longitudinal direction of the stents 12, 14 and have in each case a substantially hexagonal shape in the embodiment shown. Those skilled in the art will recognize that the mesh used to form the stent segments 22, 24, 26, and 28 may comprise a variety of other shapes known to be suitable for use in stents. For example a suitable stent may comprise mesh with repeating quadrilateral shapes, octagonal shapes, a series of curvatures, or any variety of shapes such that the stent is expandable to substantially hold a vessel or conduit at an enlarged inner diameter.
The first stent 12 may be divided into two segments 22 and 24 which may be identical to each other and typically have a tubular shape with a diameter which is substantially greater than the diameter of one of the secondary branch conduits 34. Those skilled in the art will recognize that the first stent may comprise a variety of shapes such that it functions as described herein. The first stent 12 may be expandable to a substantially cylindrical shape having a constant diameter along its length. The first stent 12 may comprise a range of lengths depending on the specific desired location of placement. For example, the length of the first stent 12 will typically be between about 1 and about 4 centimeters as desired.
The second stent 14 is preferably adapted to be deployed in close proximity to the first stent 12, and may also be divided into upper 26 and lower 28 segments. The lower segment 28 of the second stent 14 typically has a tubular cross-sectional shape and has an expanded diameter which is substantially greater than the diameter of the principal conduit 32 (
In its expanded state, as shown in
In the embodiment shown, this increase in the width of the mesh cells 36 results from an increase in the length of the edges 48 of the mesh cells 36 disposed longitudinally, as well as an increase in the angle formed between two facing edges 48.
This segment 26 thus may have a truncated shape with an axis which is oblique in relation to the longitudinal axis of the first stent 12 when expanded. This shape, for example, corresponds to the shape of the bifurcation shown in the area of the widened transitional zone 46 (
In the embodiment shown in
In addition, in other embodiments, the bridges 18 could be integral with one of the connected segments and separately connected, such as by welding, to the other connected segment. For example, the bridge 18 which connects the first and second stents 12, 14 could be integral with the upper segment 26 of the second stent 14 and connected to lower segment 24 of the first segment 26. Alternatively, the bridge 18 could be integral with the lower segment 24 of the first stent 12 and connected to the upper segment 26 of the second stent 14.
In yet other embodiments, bridges 18 could be separate pieces of materials which are separately connected to segments 22, 24, 26, 28 such as by welding, adhesion, or other bonding method. In all of these embodiments, the first stent 12 can be made from different pieces of material than the second stent 14. A tube from which the first stent 12 may be made (e.g. by laser cutting techniques) may comprise a smaller diameter than a tube from which the second stent 14 may be made. The respective tubes may or may not be made of the same material. Alternatively, the first and second stent may be formed from a single piece of material.
When the segments 26 and 28 of the second stent 14 are made from tubes of a smaller diameter than the segments 22 and 24 of the first stent 12, the radial force of the first stent segments 22 and 24 is larger than the radial force of the second stent segments 26 and 28, especially at larger cross sections.
Accordingly, bridges 18 can be made from one of these tubes, and thus be integral with segments 22 and 24 or segments 26 and 28. Alternatively, the bridges 18 can be separate pieces of material.
In further embodiments, bridges 18 are omitted such that the individual segments are spaced as desired during installation and use. These individual segments are still delivered and implanted in the same core and sheath assembly.
The bridges 18 between two consecutive segments could be greater or smaller in number than six, and they could have a shape other than an omega shape, permitting their multidirectional elasticity, and in particular a V shape or W shape.
For example,
Thus, the stent system 10 of
Alternatively, the lower segment 24 of the first stent 12 could itself have, in the expanded state, a widened shape similar to that of the second stent and corresponding to the shape of the widened connecting zone (increasing diameter in the proximal direction) by which, in certain bifurcations, the secondary conduits 34 are connected to the widened transition zone 46. Thus, the lower segment 24 of the first stent 12, or the entire first stent 12 may have a first diameter at its distal end, and a second, larger diameter at its proximal end with a linear or progressive curve (flared) taper in between. According to this embodiment, this segment 24 would thus have a shape corresponding to the shape of this widened connecting zone, and would ensure perfect support thereof.
One method of making a self-expanding stent is by appropriate cutting of a sheet of nickel/titanium alloy (for example, an alloy known by the name NITINOL may appropriately be used) into a basic shape, then rolling the resulting blank into a tubular form. The blank may be held in a cylindrical or frustroconical form by welding the opposing edges of this blank which come into proximity with each other. The stent(s) may also be formed by laser cutting from metal tube stock as is known in the art. Alternatively, a stent may be formed by selectively bending and forming a suitable cylindrical or noncylindrical tubular shape from a single or multiple wires, or thin strip of a suitable elastic material. Those skilled in the art will understand that many methods and materials are available for forming stents, only some of which are described herein.
Some Nickel Titanium alloys are malleable at a temperature of the order of 10° C. but can recover a neutral shape at a temperature substantially corresponding to that of the human body.
In one embodiment, the contraction of a stent may cause the mesh cell edges 48 to pivot in relation to the transverse edges 49 of the mesh cells 36 in such a way that the mesh cells 36 have, in this state of contraction, a substantially rectangular shape. Those skilled in the art will recognize that other materials and methods of manufacturing may be employed to create a suitable self-expanding stent.
Alternatively, the stents used may be manually expandable by use of an inflatable dilatation balloon with or without perfusion as will be discussed further below. Many methods of making balloon-expandable stents are known to those skilled in the art. Balloon expandable stents may be made of a variety of bio-compatible materials having desirable mechanical properties such as stainless steel and titanium alloys. Balloon-expandable stents preferably have sufficient radial stiffness in their expanded state that they will hold the vessel wall at the desired diameter. In the case of a balloon-expandable second stent 14, the balloon on which the second stent 14 is disposed may be specifically adapted to conform to the desired shape of the second stent 14. Specifically, such a balloon will preferably have a larger diameter at a distal end than at a proximal end.
The present discussion thus provides a pair of dissimilar stents permitting the treatment of a pathological condition in the area of a bifurcation 30. This system has the many advantages indicated above, in particular those of ensuring a perfect support of the vessel wall and of being relatively simple to position.
For the sake of simplification, the segment which has, in the unconstrained expanded state, a cross section substantially greater than the cross section of one of the secondary conduits will be referred to hereinafter as the “secondary segment”, while the segment which has, in the expanded state, a truncated shape will be referred to hereinafter as the “truncated segment.”
The secondary segment is intended to be introduced into the secondary conduit in the contracted state and when expanded will preferably bear against the wall of the conduit. This expansion not only makes it possible to treat a narrowing or a dissection situated in the area of the conduit, but also to ensure perfect immobilization of the apparatus in the conduit.
In this position, the truncated segment bears against the wall of the conduit delimiting the widened transitional zone of the bifurcation, which it is able to support fully. A narrowing or a dissection occurring at this site can thus be treated by means of this apparatus, with uniform support of the vascular wall, and thus without risk of this wall being damaged.
The two segments may be adapted to orient themselves suitably in relation to each other upon their expansion.
Advantageously, at least the truncated segment may be covered by a membrane (for example, Dacron® or ePTFE) which gives it impermeability in a radial direction. This membrane makes it possible to trap between it and the wall of the conduit, the particles which may originate from the lesion being treated, such as arteriosclerotic particles or cellular agglomerates, thus avoiding the migration of these particles in the body. Thus, the apparatus can additionally permit treatment of an aneurysm by guiding the liquid through the bifurcation and thereby preventing stressing of the wall forming the aneurysm.
The segments can be made from tubes of material of a different diameter, as discussed above, with the tube for the truncated segment having a larger diameter than the tube for the secondary segment. The tubes may be made from the same material. The use of tubes of different diameters can result in the truncated segment having a larger radial force, especially at larger diameters.
The apparatus can comprise several secondary segments, placed one after the other, to ensure supplementary support of the wall of the secondary conduit and, if need be, to increase the anchoring force of the stent in the bifurcation. To this same end, the apparatus can comprise, on that side of the truncated segment directed toward the principal conduit, at least one radially expandable segment having, in the expanded state, a cross section which is substantially greater than the cross section of the principal conduit.
These various supplementary segments may or may not be connected to each other and to the two aforementioned segments by means of flexible links, such as those indicated above.
The flexible links can be integral with one of the segments and separately connected to the other segment, or the flexible links can be separate pieces of material separately connected to both segments, such as by welding.
Preferably, the flexible link between two consecutive segments is made up of one or more bridges of material connecting the two adjacent ends of these two segments. Said bridge or bridges are advantageously made of the same material as that forming the segments.
Each segment may have a meshwork structure, the meshes being elongated in the longitudinal direction of the stent, and each one having a substantially hexagonal shape; the meshes of the truncated segment may have a width which increases progressively in the longitudinal sense of the stent, in the direction of the end of this segment having the greatest cross section in the expanded state.
This increase in the width of the meshes is the result of an increase in the length of the edges of the meshes disposed longitudinally and/or an increase in the angle formed between two facing edges of the same mesh.
In addition, the truncated segment can have an axis not coincident with the longitudinal axis of the secondary segment, but oblique in relation to this axis, in order to be adapted optimally to the anatomy of the bifurcation which is to be treated. In this case, the widths of the meshes of the truncated segment also increase progressively, in the transverse sense of the stent, in the direction of a generatrix diametrically opposite that located in the continuation of the bridge connecting this segment to the adjacent segment.
The apparatus can be made of a metal with shape memory, which becomes malleable, without elasticity, at a temperature markedly lower than that of the human body, in order to permit retraction of the apparatus upon itself, and to allow it to recover its neutral shape at a temperature substantially corresponding to that of the human body. This metal may be a nickel/titanium alloy known by the name NITINOL.
The deployment catheter for positioning the stent or stents comprises means for positioning the stents and means for permitting the expansion of the stents when the latter are in place. These means can comprise a catheter having a removable sheath in which the stent is placed in the contracted state, when this stent is made of an elastic material, or a support core comprising an inflatable balloon on which the stent is placed, when this stent is made of a nonelastic material.
In either case, this equipment comprises, according to the invention, means with which it is possible to identify and access, through the body of the patient, the longitudinal location of the truncated segment, so that the latter can be correctly positioned in the area of the widened zone of the bifurcation.
In the case where the expansion of this same segment is not uniform in relation to the axis of the stent, the equipment additionally comprises means with which it is possible to identify, through the body of the patient, the angular orientation of the stent in relation to the bifurcation to be treated, so that the part of this segment having the greatest expansion can be placed in a suitable manner in relation to the bifurcation.
Referring to
The elongate delivery catheter 100 generally includes a proximal end assembly 102, a proximal shaft section 110 including a tubular body 111, a distal shaft section 120 including a distal tubular body 113, and a distal end assembly 107. The proximal end 102 may include a handpiece 140, having one or more hemostatic valves and/or access ports 106, such as for the infusion of drugs, contrast media or inflation media in a balloon expandable stent embodiment, as will be understood by those of skill in the art. In addition, a proximal guidewire port 172 may be provided on the handpiece 140 in an over the wire embodiment (see
The length of the catheter depends upon the desired application. For example, lengths in the area of about 120 cm to about 140 cm are typical for use in coronary applications reached from a femoral artery access. Intracranial or lower carotid artery applications may call for a different catheter shaft length depending upon the vascular access site, as will be apparent to those of skill in the art.
The catheter 100 preferably has as small an outside diameter as possible to minimize the overall outside diameter (e.g. crossing profile) of the delivery catheter, while at the same time providing sufficient column strength to permit distal transluminal advancement of the tapered tip 122. The catheter 100 also preferably has sufficient column strength to allow an outer, axially moveable sheath 114 to be proximally retracted relative to the central core 112 in order to expose the stents 118. The delivery catheter 100 may be provided in either “over-the-wire” or “rapid exchange” types as will be discussed further below, and as will generally be understood by those skilled in the art.
In a catheter intended for peripheral vascular applications, the outer sheath 114 will typically have an outside diameter within the range of from about 0.065 inches to about 0.092 inches. In coronary vascular applications, the outer sheath 114 may have an outside diameter with the range of from about 0.039 inches to about 0.065. Diameters outside of the preferred ranges may also be used, provided that the functional consequences of the diameter are acceptable for the intended purpose of the catheter. For example, the lower limit of the diameter for any portion of catheter 100 in a given application will be a function of the number of guidewire, pullwire or other functional lumen contained in the catheter, together with the acceptable minimum flow rate of dilatation fluid, contrast media or drugs to be delivered through the catheter and minimum contracted stent diameter.
The ability of the catheter 100 to transmit torque may also be desirable, such as to avoid kinking upon rotation, to assist in steering, and in embodiments having an asymmetrical distal end on the proximal stent 14a. The catheter 100 may be provided with any of a variety of torque and/or column strength enhancing structures, for example, axially extending stiffening wires, spiral wrapped support layers, or braided or woven reinforcement filaments which may be built into or layered on the catheter 100. See, for example, U.S. Pat. No. 5,891,114 to Chien, et al., the disclosure of which is incorporated in its entirety herein by reference.
Referring to
At the distal end 107, the catheter is adapted to retain and deploy one or more stents within a conduit of a human body. With reference to
The outer sheath 114 may extend over a substantial length of the catheter 100, or may comprise a relatively short length, distal to the proximal guidewire access port 172 as will be discussed. In general, the outer sheath 114 is between about 5 and about 25 cm long.
Referring to
The outer sheath 114 and inner core 112 may be produced in accordance with any of a variety of known techniques for manufacturing rapid exchange or over the wire catheter bodies, such as by extrusion of appropriate biocompatible polymeric materials. Known materials for this application include high and medium density polyethylenes, polytetrafluoroethylene, nylons, PEBAX, PEEK, and a variety of others such as those disclosed in U.S. Pat. No. 5,499,973 to Saab, the disclosure of which is incorporated in its entirety herein by reference. Alternatively, at least a proximal portion or all of the length of central core 112 and/or outer sheath 114 may comprise a metal or polymeric spring coil, solid walled hypodermic needle tubing, or braided reinforced wall, as is understood in the catheter and guidewire arts.
The distal portion 117 of outer sheath 114 is positioned concentrically over the stents 118 in order to hold them in their contracted state. As such, the distal portion 117 of the outer sheath 114 is one form of a releasable restraint. The releasable restraint preferably comprises sufficient radial strength that it can resist deformation under the radial outward bias of a self-expanding stent. The distal portion 117 of the outer sheath 114 may comprise a variety of structures, including a spring coil, solid walled hypodermic needle tubing, banded, or braided reinforced wall to add radial strength as well as column strength to that portion of the outer sheath 114. Alternatively, the releasable restraint may comprise other elements such as water soluble adhesives or other materials such that once the stents are exposed to the fluid environment and/or the temperature of the blood stream, the restraint material will dissolve, thus releasing the self-expandable stents. A wide variety of biomaterials which are absorbable in an aqueous environment over different time intervals are known including a variety of compounds in the polyglycolic acid family, as will be understood by those of skill in the art. In yet another embodiment, a releasable restraint may comprise a plurality of longitudinal axial members disposed about the circumference of the stents. According to this embodiment anywhere from one to ten or more axial members may be used to provide a releasable restraint. The axial members may comprise cylindrical rods, flat or curved bars, or any other shape determined to be suitable.
In some situations, self expanding stents will tend to embed themselves in the inner wall of the outer sheath 114 over time. As illustrated in
The inner surface of the outer sheath 114, and/or the outer surface of the central core 112 may be further provided with a lubricious coating or lining such as Paralene, Teflon, silicone, polyimide-polytetrafluoroethylene composite materials or others known in the art and suitable depending upon the material of the outer sheath 114 and/or central core 112.
As illustrated in
The pull wire slot 224 is preferably of sufficient length to allow the sheath 114 to be fully retracted. Thus, the pull wire slot 224 is preferably at least as long as the distance from the distal end of the stent stop 218 to the distal end of the sheath 114 as shown in
In yet another embodiment illustrated for example in
The pull wire 222 may comprise a variety of suitable profiles known to those skilled in the art, such as round, flat straight, or tapered. The diameter of a straight round pull wire 222 may be between about 0.008″ and about 0.018″ and in one embodiment is about 0.009″. In another embodiment, the pull wire 222 has a multiple tapered profile with diameters of 0.015″, 0.012″, and 0.009″ and a distal flat profile of 0.006″×0.012″. The pull wire 222 may be made from any of a variety of suitable materials known to those skilled in the art, such as stainless steel or nitinol, and may be braided or single strand and may be coated with a variety of suitable materials such as Teflon, Paralene, etc. The wire 222 has sufficient tensile strength to allow the sheath 114 to be retracted proximally relative to the core 112. In some embodiments, the wire 222 may have sufficient column strength to allow the sheath 114 to be advanced distally relative to the core 112 and stents 12a, 14a. For example, if the distal stent 12a has been partially deployed, and the clinician determines that the stent 12a should be re-positioned, the sheath 114 may be advanced distally relative to the stent 12a thereby re-contracting and capturing that stent on the core.
In general, the tensile strength or compressibility of the pull wire 222 may also be varied depending upon the desired mode of action of the outer sheath 114. For example, as an alternative to the embodiment described above, the outer sheath 114 may be distally advanced by axially distally advancing the pull wire 222, to release the stent 118. In a hybrid embodiment, the outer sheath 114 is split into a proximal portion and a distal portion. A pull wire is connected to the proximal portion, to allow proximal retraction to release the proximal stent. A push wire is attached to the distal portion, to allow distal advance, thereby releasing the distal stent. These construction details of the catheter 100 and nature of the wire 222 may be varied to suit the needs of each of these embodiments, as will be apparent to those skilled in the art in view of the disclosure herein.
The stents 118 are carried on the central support core 112, and are contracted radially thereon. By virtue of this contraction, the stents 118 have a cross section which is smaller than that of the conduits 32 and 34, and they can be introduced into these as will be described below. The stents 118 are preferably disposed on a radially inwardly recessed distal portion 129 of the central core 112 having a smaller diameter than the adjacent portions of the core 112. This recess 129 is preferably adjacent a distal abutment such as a shoulder 124 which may be in the form of a proximally facing surface on a distal tip 122. Distal tip 122 has an outer diameter smaller than that of the stents 118 when the stents are expanded, but greater than the diameter of the stents 118 when they are contracted. This abutment 124 consequently prevents distal advancement of the stents 118 from the core 112 when the stents 118 are contracted.
Proximal movement of the stents 118 relative to the core 112 is prevented when the stents are in the radially contracted configuration by a proximal abutment surface such as annular shoulder 125. The distal abutment 124 and proximal abutment 125 may be in the form of annular end faces formed by the annular recess 129 in the core 112, for receiving the compressed stents 118. See
The deployment device 100 typically has a soft tapered tip 122 secured to the distal end of inner core 112, and usually has a guidewire exit port 126 as is known in the art. The tapered distal tip 122 facilitates insertion and atraumatic navigation of the vasculature for positioning the stent system 118 in the area of the bifurcation to be treated. The distal tip 122 can be made from any of a variety of polymeric materials well known in the medical device arts, such as polyethylene, nylon, PTFE, and PEBAX. In the embodiment shown in
The distal tip 122 tapers in one embodiment from an outside diameter which is substantially the same as the outer diameter of the outer sheath 114 at the proximal end 128 of the tip 122 to an outside diameter at its distal end 130 of slightly larger than the outside diameter of a guidewire. The overall length of the distal tip 122 in one embodiment of the delivery catheter 100 is about 3 mm to about 12 mm, and in one embodiment the distal tip is about 8 mm long. The length and rate of taper of the distal tip 122 can be varied depending upon the desired trackability and flexibility characteristics. The tip 122 may taper in a linear, curved or any other manner known to be suitable.
With reference to
In the construction shown in cross-section in
In one embodiment, the proximal shaft tube 111 comprises a stainless steel hypodermic needle tubing having an outside diameter of about 0.025″ and a wall thickness of about 0.003″. The distal end 123 of the hypotube is cut or ground into a tapered configuration. The axial length of the tapered zone may be varied widely, depending upon the desired flexibility characteristics of the catheter 100. In general, the axial length of the taper is within the range of from about 1 cm to about 5 cm, and, in one embodiment, is about 2.5 cm. Tapering the distal end of the hypotube at the transition with the distal portion of the catheter provides a smooth transition of the flexibility characteristics along the length of the catheter, from a relatively less flexible proximal section to a relatively more flexible distal section as will be understood by those of skill in the art.
Referring to
As shown in
The inflatable balloon 116, if present, may be positioned beneath one or both stents, such as stent 14a as illustrated in
As seen in
The illustrated control 150 is preferably moveable from a first position to a second position for partial deployment of the first stent 12a, and a third position for complete deployment of the first stent 12a. A fourth and a fifth positions are also provided to accomplish partial and complete deployment of the second stent 14a. The control 150 may include indicia 160 adapted to indicate the amount of each stent 12a or 14a which has been exposed as the sheath 114 is retracted relative to the core 112. The indicia 160 may include dents, notches, or other markings to visually indicate the deployment progress. The control 150 may also or alternatively provide audible and/or tactile feedback using any of a variety of notches or other temporary catches to cause the slider to “click” into positions corresponding to partial and full deployment of the stents 12a, 14a. Alignable points of electrical contact may also be used. Those skilled in the art will recognize that many methods and structures are available for providing a control 150 as desired.
The catheter 100 may include a plurality of radiopaque markers 250 (seen best in
With reference to
A central marker 252 makes it possible to visualize, with the aid of a suitable radiography apparatus, the position of a bridge 18 or the two stents 12a, 14a. Thus allowing a specialist to visualize the location of the second stent 14a so that it can be correctly positioned in relation to the widened zone 46. The end markers 250A allow a specialist to ensure that the stents 12a, 14a are correctly positioned, respectively, in the main/principal conduit 32 and the secondary/branch conduit 34.
A diamond-shaped marker 252 as shown in
Methods of positioning and deploying a pair of dissimilar stents in an area of a bifurcation will now be discussed with reference to
A method of delivering a stent system as described above generally and illustrated in
The delivery catheter 100 may be constructed according to any of the embodiments described above such that the stents 12a, 14a may be selectively deployed by axially displacing the outer sheath 114 along the delivery catheter, thereby selectively exposing the stent system 10. This may be accomplished by holding the sheath 114 fixed relative to the bifurcation, and selectively distally advancing the central core 112. Thus, the present invention contemplates deploying one or more stents by distally advancing the central core (inner sheath) rather than proximally retracting the outer sheath as a mode of stent deployment. The stent system may alternatively be deployed by holding the central core fixed relative to the bifurcation and selectively proximally retracting the sheath 114. The catheter may also be adapted to allow the sheath to be advanced distally, thereby re-contracting the partially deployed stents on the central core 112 to allow repositioning or removal.
In order to visualize the position of a partially-deployed stent with a suitable radiographic apparatus, a contrast media may be introduced through the catheter to the region of the stent placement. Many suitable contrast media are known to those skilled in the art. The contrast media may be introduced at any stage of the deployment of the stent system 10. For example, a contrast media may be introduced after partially deploying the first stent 12a, after fully deploying the first stent 12a, after partially deploying the second stent 14a, or after fully deploying the second stent 14a.
The degree of deployment of the stent system 10 is preferably made apparent by the indicators on the handpiece 200 as described above. The handpiece 200 and outer sheath are preferably adapted such that a motion of a control on the handpiece 200 results in proximal motion of the outer sheath 114 relative to the distal tip 122 and the stents 12a, 14a. The handpiece 140 and sheath 114 may also be adapted such that the sheath may be advanced distally relative to the stents 12a, 14a, thus possibly re-contracting one of the stents 12a, 14a on the core 112. This may be accomplished by providing a pull wire 222 having a distal end 223 attached to a portion of the outer sheath 114, and a proximal end adapted to be attached to the handpiece 200. Alternatively, the handpiece 200 may be omitted, and the retraction wire 206 may be directly operated by the clinician.
In an alternative embodiment, indicated by
In a preferred embodiment, the second stent 14a is placed in close proximity to the first stent 12a. For example, the distal end 38 of the second stent 14a may be placed within a distance of about 4 mm of the proximal end 42 of the first stent 12a, more preferably this distance is less than about 2 mm, and most preferably the first and second stents 12a, 14a are placed within 1 mm of one another. Those skilled in the art will recognize that the relative positioning of the first and second stents 12a, 14a will at least partially depend on the presence or absence of a bridge 18 as discussed above. The axial flexibility of any bridge 18 will also affect the degree of mobility of one of the stents relative to the other. Thus, a stent system 10 will preferably be chosen to best suit the particular bifurcation to be treated.
As mentioned above, the stents 12a, 14a may be self-expanding or balloon-expandable (e.g. made of a substantially non-elastic material). Thus the steps of partially deploying the first and/or the second stent may include introducing an inflation fluid into a balloon on which a stent is disposed, or alternatively the stent may be allowed to self-expand. In the case of a balloon-expandable second stent 14a, the balloon 116 (
After complete expansion of the stents 12a, 14a, the distal end of the delivery catheter 100 including the core 112 and the guidewire 170 may be withdrawn from the conduits and the vasculature of the patient. Alternatively, additional stents may also be provided on a delivery catheter, which may also be positioned and deployed in one or both branches of the bifurcation. For example, after deploying the second stent 14, 14a as shown in
Referring to
As will be clear to those skilled in the art, the stent system 10 and stent delivery system 100 described herein is useful in treating a number of pathological conditions commonly found in vascular systems and other fluid conduit systems of human patients. Treatment with the apparatus can include re-establishing the appropriate diameter of a bifurcation in cases of arteriosclerosis or internal cell proliferation, or in rectifying a localized or nonlocalized dissection in the wall of the conduit, or in re-creating a bifurcation of normal diameter while eliminating the aneurysmal pouch in cases of aneurysm.
One or more of the stents deployed in accordance with the present invention may be coated with or otherwise carry a drug to be eluted over time at the bifurcation site. Any of a variety of therapeutically useful agents may be used, including but not limited to, for example, agents for inhibiting restenosis, inhibiting platelet aggregation, or encouraging endothelialization. Some of the suitable agents may include smooth muscle cell proliferation inhibitors such as rapamycin, angiopeptin, and monoclonal antibodies capable of blocking smooth muscle cell proliferation; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, acetyl salicylic acid, and mesalamine, lipoxygenase inhibitors; calcium entry blockers such as verapamil, diltiazem and nifedipine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, methotrexate, doxorubicin, daunorubicin, cyclosporine, cisplatin, vinblastine, vincristine, colchicine, epothilones, endostatin, angiostatin, Squalamine, and thymidine kinase inhibitors; L-arginine; antimicrobials such astriclosan, cephalosporins, aminoglycosides, and nitorfuirantoin; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; nitric oxide (NO) donors such as lisidomine, molsidomine, NO-protein adducts, NO-polysaccharide adducts, polymeric or oligomeric NO adducts or chemical complexes; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, enoxaparin, hirudin, Warafin sodium, Dicumarol, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; interleukins, interferons, and free radical scavengers; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promotors; vascular cell growth inhibitors such as growth factor inhibitors (e.g., PDGF inhibitor—Trapidil), growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; Tyrosine kinase inhibitors, chymase inhibitors, e.g., Tranilast, ACE inhibitors, e.g., Enalapril, MMP inhibitors, (e.g., Ilomastat, Metastat), GP IIb/IIIa inhibitors (e.g., Intergrilin, abciximab), seratonin antagnonist, and 5-HT uptake inhibitors; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogeneus vascoactive mechanisms. Polynucleotide sequences may also function as anti-restenosis agents, such as p15, p16, p18, p19, p21, p27, p53, p57, Rb, nFkB and E2F decoys, thymidine kinase (“TK”) and combinations thereof and other agents useful for interfering with cell proliferation. The selection of an active agent can be made taking into account the desired clinical result and the nature of a particular patient's condition and contraindications.
The bifurcation 30 shown in
As shown in
The stent system described may be adapted as mentioned above to treat any of a number of bifurcations within a human patient. For example, bifurcations of both the left and right coronary arteries, the bifurcation of the circumflex artery, the carotid, femoral, iliac, popliteal, renal or coronary bifurcations. Alternatively this apparatus may be used for nonvascular bifurcations, such as tracheal or biliary bifurcations, for example between the common bile and cystic ducts, or in the area of the bifurcation of the principal bile tract.
Although certain preferred embodiments and examples have been described herein, it will be understood by those skilled in the art that the present inventive subject matter extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Thus, it is intended that the scope of the present inventive subject matter herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
Number | Date | Country | Kind |
---|---|---|---|
96 07245 | Jun 1996 | FR | national |
This is a continuation of U.S. application Ser. No. 10/225,484, filed Aug. 20, 2002, now U.S. Pat. No. 7,238,197, which is a continuation-in-part of U.S. application Ser. No. 09/580,597, filed May 30, 2000, now U.S. Pat. No. 6,666,883, which is a continuation-in-part of U.S. application Ser. No. 09/011,214, filed Apr. 3, 1998, now U.S. Pat. No. 6,068,655, which is the national stage of International Application No. PCT/FR97/00999, filed Jun. 5, 1997, which claims priority from French Application No. FR 96-07245, filed Jun. 6, 1996, the disclosures of which are all incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3805301 | Liebig | Apr 1974 | A |
3818511 | Goldberg et al. | Jun 1974 | A |
3945052 | Liebig | Mar 1976 | A |
4390599 | Broyles | Jun 1983 | A |
4562596 | Kornberg | Jan 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4733065 | Hoshi et al. | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4806062 | Stier | Feb 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4994071 | MacGregor | Feb 1991 | A |
5019090 | Pinchuk et al. | May 1991 | A |
5045072 | Castillo et al. | Sep 1991 | A |
5064435 | Porter | Nov 1991 | A |
5102417 | Palmaz | Apr 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5135536 | Hillstead | Aug 1992 | A |
5192297 | Hull | Mar 1993 | A |
5195984 | Schatz | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5211658 | Clouse et al. | May 1993 | A |
5211663 | Kovacs et al. | May 1993 | A |
5219355 | Parodi et al. | Jun 1993 | A |
5234457 | Andersen | Aug 1993 | A |
5282824 | Gianturco | Feb 1994 | A |
5330500 | Song | Jul 1994 | A |
5356423 | Tihon | Oct 1994 | A |
5360401 | Turnland | Nov 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5405378 | Strecker | Apr 1995 | A |
5443498 | Fontaine | Aug 1995 | A |
5445646 | Euteneuer et al. | Aug 1995 | A |
5456713 | Chuter | Oct 1995 | A |
5466242 | Mori | Nov 1995 | A |
5499973 | Saab | Mar 1996 | A |
5510077 | Dinh et al. | Apr 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5514178 | Torchio | May 1996 | A |
5540701 | Sharkey et al. | Jul 1996 | A |
5562697 | Christiansen | Oct 1996 | A |
5562724 | Vorwerk et al. | Oct 1996 | A |
5562726 | Chuter | Oct 1996 | A |
5571135 | Fraser | Nov 1996 | A |
5571168 | Toro | Nov 1996 | A |
5571170 | Palmaz et al. | Nov 1996 | A |
5571173 | Parodi | Nov 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5603721 | Lau et al. | Feb 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5653743 | Martin | Aug 1997 | A |
5667486 | Mikulich et al. | Sep 1997 | A |
5669880 | Solar | Sep 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5676696 | Marcade | Oct 1997 | A |
5683449 | Marcade | Nov 1997 | A |
5683451 | Lenker | Nov 1997 | A |
5693084 | Chuter | Dec 1997 | A |
5695499 | Helgerson et al. | Dec 1997 | A |
5707376 | Kavteladze et al. | Jan 1998 | A |
5716393 | Lindenberg et al. | Feb 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5720776 | Chuter et al. | Feb 1998 | A |
5735893 | Lau et al. | Apr 1998 | A |
5741327 | Frantzen | Apr 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755769 | Richard et al. | May 1998 | A |
5755770 | Ravenscroft | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5772669 | Vrba | Jun 1998 | A |
5776142 | Gunderson | Jul 1998 | A |
5776184 | Tuch | Jul 1998 | A |
5788707 | Del Toro et al. | Aug 1998 | A |
5797951 | Mueller | Aug 1998 | A |
5797952 | Klein | Aug 1998 | A |
5800514 | Nunez et al. | Sep 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5820542 | Dobakk, III et al. | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5824042 | Lombardi et al. | Oct 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5833694 | Poncet | Nov 1998 | A |
5849037 | Frid | Dec 1998 | A |
5851217 | Wolff et al. | Dec 1998 | A |
5851228 | Pinheiro | Dec 1998 | A |
5851231 | Wolff et al. | Dec 1998 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5891114 | Chien et al. | Apr 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5897588 | Hull et al. | Apr 1999 | A |
5904713 | Leschinsky | May 1999 | A |
5910129 | Koblish et al. | Jun 1999 | A |
5922019 | Hankh et al. | Jul 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5957930 | Vrba | Sep 1999 | A |
5957949 | Leonhardt | Sep 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
5980484 | Ressemann et al. | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5984955 | Wisselink | Nov 1999 | A |
5989280 | Euteneuer et al. | Nov 1999 | A |
5993481 | Marcade et al. | Nov 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6030415 | Chuter | Feb 2000 | A |
6042588 | Munsinger et al. | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6053941 | Lindenberg et al. | Apr 2000 | A |
6056776 | Lau et al. | May 2000 | A |
6059813 | Vrba et al. | May 2000 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066167 | Lau et al. | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6077296 | Shokoohi et al. | Jun 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096071 | Yadav | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6117140 | Munsinger | Sep 2000 | A |
6120522 | Vrba et al. | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6143016 | Bleam et al. | Nov 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6159239 | Greenhalgh | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6179858 | Squire et al. | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6197049 | Shaolian et al. | Mar 2001 | B1 |
6203568 | Lombardi | Mar 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210431 | Power | Apr 2001 | B1 |
6221090 | Wilson | Apr 2001 | B1 |
6221098 | Wilson et al. | Apr 2001 | B1 |
6228110 | Munsinger | May 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6245100 | Davila et al. | Jun 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6258121 | Yang et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264682 | Wilson et al. | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6283992 | Hankh et al. | Sep 2001 | B1 |
6293966 | Frantzen | Sep 2001 | B1 |
6302893 | Limon et al. | Oct 2001 | B1 |
6305436 | Andersen et al. | Oct 2001 | B1 |
6309412 | Lau et al. | Oct 2001 | B1 |
6315794 | Richter | Nov 2001 | B1 |
6322847 | Zhong et al. | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6325820 | Khosravi et al. | Dec 2001 | B1 |
6330884 | Kim | Dec 2001 | B1 |
6331186 | Wang et al. | Dec 2001 | B1 |
6334871 | Dor et al. | Jan 2002 | B1 |
6340368 | Verbeck | Jan 2002 | B1 |
6346118 | Baker et al. | Feb 2002 | B1 |
6358556 | Ding et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361557 | Gittings et al. | Mar 2002 | B1 |
6375676 | Cox | Apr 2002 | B1 |
6391050 | Broome | May 2002 | B1 |
6391051 | Sullivan, III et al. | May 2002 | B2 |
6395017 | Dwyer et al. | May 2002 | B1 |
6398807 | Chouinard et al. | Jun 2002 | B1 |
6402777 | Globerman et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6409752 | Boatman et al. | Jun 2002 | B1 |
6409755 | Vrba | Jun 2002 | B1 |
6413269 | Bui et al. | Jul 2002 | B1 |
6416542 | Marcade et al. | Jul 2002 | B1 |
6428566 | Holt | Aug 2002 | B1 |
6440165 | Richter et al. | Aug 2002 | B1 |
6458867 | Wang et al. | Oct 2002 | B1 |
6464721 | Marcade et al. | Oct 2002 | B1 |
6471721 | Dang | Oct 2002 | B1 |
6475208 | Mauch | Nov 2002 | B2 |
6475236 | Roubin et al. | Nov 2002 | B1 |
6488700 | Klumb et al. | Dec 2002 | B2 |
6491681 | Kunis et al. | Dec 2002 | B1 |
6491938 | Kunz et al. | Dec 2002 | B2 |
6494875 | Mauch | Dec 2002 | B1 |
6497916 | Taylor et al. | Dec 2002 | B1 |
6503271 | Duerig et al. | Jan 2003 | B2 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6514281 | Blaeser et al. | Feb 2003 | B1 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6527789 | Lau et al. | Mar 2003 | B1 |
6533810 | Hankh et al. | Mar 2003 | B2 |
6562063 | Euteneuer et al. | May 2003 | B1 |
6592615 | Marcade et al. | Jul 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6610087 | Zarbatany et al. | Aug 2003 | B1 |
6613072 | Lau et al. | Sep 2003 | B2 |
6613075 | Healy et al. | Sep 2003 | B1 |
6620194 | Ding et al. | Sep 2003 | B2 |
6648913 | Vee et al. | Nov 2003 | B1 |
6652579 | Cox et al. | Nov 2003 | B1 |
6656212 | Ravenscroft et al. | Dec 2003 | B2 |
6660030 | Shaolian et al. | Dec 2003 | B2 |
6663665 | Shaolian et al. | Dec 2003 | B2 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6669719 | Wallace et al. | Dec 2003 | B2 |
6689159 | Lau et al. | Feb 2004 | B2 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695875 | Stelter | Feb 2004 | B2 |
6699274 | Stinson | Mar 2004 | B2 |
6702846 | Mikus et al. | Mar 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6709440 | Callol et al. | Mar 2004 | B2 |
6733523 | Shaolian | May 2004 | B2 |
6780174 | Mauch | Aug 2004 | B2 |
6827735 | Greenberg | Dec 2004 | B2 |
6863685 | Davila et al. | Mar 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6964681 | Murray, III | Nov 2005 | B2 |
7125419 | Sequin et al. | Oct 2006 | B2 |
7160318 | Greenberg et al. | Jan 2007 | B2 |
7238197 | Sequin et al. | Jul 2007 | B2 |
7243408 | Vietmeier | Jul 2007 | B2 |
7344556 | Seguin et al. | Mar 2008 | B2 |
7686845 | Sequin et al. | Mar 2010 | B2 |
20010004705 | Killion et al. | Jun 2001 | A1 |
20010010013 | Cox et al. | Jul 2001 | A1 |
20010012943 | Shaolian et al. | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010037142 | Stelter et al. | Nov 2001 | A1 |
20010044595 | Reydel et al. | Nov 2001 | A1 |
20010044622 | Vardi et al. | Nov 2001 | A1 |
20020016597 | Dwyer et al. | Feb 2002 | A1 |
20020035389 | Pinchasik et al. | Mar 2002 | A1 |
20020058984 | Butaric et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020107330 | Pinchuk et al. | Aug 2002 | A1 |
20020123791 | Harrison | Sep 2002 | A1 |
20020143386 | Davila et al. | Oct 2002 | A1 |
20020198587 | Greenberg et al. | Dec 2002 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030130720 | DePalma et al. | Jul 2003 | A1 |
20030139796 | Sequin et al. | Jul 2003 | A1 |
20030139803 | Sequin et al. | Jul 2003 | A1 |
20030144724 | Murray, III | Jul 2003 | A1 |
20030163188 | Haverkost et al. | Aug 2003 | A1 |
20030181973 | Sahota | Sep 2003 | A1 |
20030187494 | Loaldi | Oct 2003 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040098114 | Wilson et al. | May 2004 | A1 |
20040102838 | Killion et al. | May 2004 | A1 |
20050049680 | Fischell et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20060069421 | Murray, III | Mar 2006 | A1 |
20060100685 | Seguin et al. | May 2006 | A1 |
20060142849 | Killion et al. | Jun 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20070067011 | Krolik et al. | Mar 2007 | A1 |
20070100425 | Sequin et al. | May 2007 | A1 |
20080046072 | Laborde et al. | Feb 2008 | A1 |
20080161903 | Sequin et al. | Jul 2008 | A1 |
20100256744 | Laborde et al. | Oct 2010 | A1 |
Number | Date | Country |
---|---|---|
0335341 | Oct 1989 | EP |
0520721 | Jun 1992 | EP |
666065 | Aug 1995 | EP |
0 421 729 | Jan 1996 | EP |
0698380 | Feb 1996 | EP |
0941716 | Sep 1999 | EP |
2722678 | Jan 1996 | FR |
01299550 | Dec 1989 | JP |
3151983 | Jun 1991 | JP |
04-064367 | Feb 1992 | JP |
6-007454 | Jan 1994 | JP |
07308331 | Nov 1995 | JP |
11-512635 | Nov 1999 | JP |
2001-245886 | Mar 2000 | JP |
WO 9412136 | Jun 1994 | WO |
WO 9521592 | Aug 1995 | WO |
WO 9532757 | Dec 1995 | WO |
WO 9614028 | May 1996 | WO |
WO 9313824 | Jul 1996 | WO |
WO 9629955 | Oct 1996 | WO |
WO 9634580 | Nov 1996 | WO |
WO 9637167 | Nov 1996 | WO |
WO 9707752 | Mar 1997 | WO |
WO 9712562 | Apr 1997 | WO |
WO 9746174 | Dec 1997 | WO |
WO 9836709 | Aug 1998 | WO |
WO 9915103 | Apr 1999 | WO |
WO 9937242 | Jul 1999 | WO |
WO 0044307 | Aug 2000 | WO |
WO0139697 | Jun 2001 | WO |
WO 0160284 | Aug 2001 | WO |
WO 02060520 | Aug 2002 | WO |
WO 2004017865 | Mar 2004 | WO |
WO 2004041126 | May 2004 | WO |
WO 2004043301 | May 2004 | WO |
WO 2008131266 | Oct 2008 | WO |
Entry |
---|
U.S. Patent No. 6,068,655 filed Jun. 5, 1997 including prosecution history. |
U.S. Patent No. 6,666,883 filed May 30, 2000 including prosecution history. |
U.S. Patent No. 7,344,556 filed May 9, 2003 including prosecution history, including but not limited to Restriction Requirement of May 19, 2005, Non-Final Office Action of Sep. 9, 2005, Final Office Action of Mar. 22, 2006, and Non-Final Office Action of Aug. 10, 2006. |
U.S. Patent Application Publication No. 2008/0161903 filed Mar. 17, 2008 including prosecution history. |
U.S. Patent Application Publication No. 2007/0100425 filed Oct. 24, 2006 including prosecution history. |
U.S. Patent Application Publication No. 2006/0100685 filed May 9, 2005 including prosecution history, including but not limited to Non-Final Office Action of Jun. 5, 2008 and Non-Final Office Action of Feb. 12, 2009. |
U.S. Patent No. 7,238,197 filed Aug. 20, 2002 including prosecution history, including but not limited to Restriction Requirement of Mar. 31, 2004, Non-Final Office Action of Mar. 22, 2005, Non-Final Office Action of Jan. 5, 2006, and Final Office Action of Jun. 16, 2006. |
U.S. Appl. No. 10/292,385, filed Nov. 11, 2002 including prosecution history, including but not limited to Restriction Requirement of Mar. 23, 2004, Non-Final Office Action of May 29, 2007, Final Office Action of Mar. 25, 2008, Non-Final Office Action of Aug. 22, 2008 and Final Office Action of Mar. 19, 2009. |
U.S. Appl. No. 10/304,085, filed Nov. 11, 2002 including prosecution history, including but not limited to Restriction Requirement of Mar. 1, 2005, Non-Final Office Action of May 22, 2007, Final Office Action of Mar. 20, 2008, Non-Final Office Action of Jul. 22, 2008, Non-Final Office Action of Mar. 11, 2009 and Final Office Action of Mar. 19, 2009. |
U.S. Patent No. 7,344,556 filed May 9, 2003 including prosecution history, including but not limited to Non-Final Office Action of May 19, 2005, Non-Final Office Action of Sep. 9, 2005, Final Office Action of Mar. 22, 2006, and Non-Final Office Action of Aug. 10, 2006. |
U.S. Patent Application Publication No. 2008/0046072 filed Apr. 19, 2007 including prosecution history, including but not limited to Restriction Requirement of Nov. 26, 2008 and Non-final Office Action of Feb. 4, 2009. |
U.S. Patent No. 7,125,419 filed Oct. 28, 2002 including prosecution history, including but not limited to Restriction Requirement of Jun. 30, 2004, Non-Final Office Action of Dec. 2, 2004, Non-final Office Action of Jun. 23, 2005, and Final Office Action of Oct. 13, 2008. |
U.S. Publication Application No. 2005/0096726 filed Oct. 29, 2004 including prosecution history, including but not limited to Non-final Office Action of Sep. 19, 2007, Final Office Action of Apr. 24, 2008, and Non-Final Office Action of Oct. 14, 2008. |
International Search Report for International Application No. PCT/EP02/12509, mailed on Sep. 30, 2003, in 4 pages. |
International Search Report for International Application No. PCT/US03/35714, mailed on Apr. 19, 2004, in 2 pages. |
International Search Report for International Application No. PCT/US03/25988, mailed on Aug. 1, 2004, in 4 pages. |
International Search Report for International Application No. PCT/US08/60884, mailed on Sep. 2, 2008, in 1 page. |
Supplementary European Search Report for Application No. EP 03768812.4, dated Nov. 27, 2008, in 3 pages. |
International Search Report for International App. No. PCT/FR97/00999, mailed on May 11, 1997. |
Examination Report of May 21, 2007 for Australian Patent Application No. 2003259932. |
Examination Report of Sep. 19, 2007 for Australian Patent Application No. 2002356575. |
Examination Report of Jan. 16, 2008 for Australian Patent Application No. 2003291416. |
Examination Report of Sep. 11, 2008 for European Patent Application No. 03793137.5. |
Examination Report of Jan. 23, 2007 for European Patent Application No. 02808089.3. |
Examination Report of Dec. 13, 2007 for European Patent Application No. 02808089.3. |
Examination Report of Feb. 5, 2009 for Japanese Patent Application No. 2004-548704. |
Foreign Office Action received in Canadian Patent Application No. 2,505,137 of Nov. 12, 2008, in 2 pages. |
Japanese Patent Application No. H10-500284 filed Jun. 5, 1997 including Foreign Office Action of Jun. 20, 2006 in 5 pages and Foreign Office Action of Mar. 6, 2007 in 1 page. |
European Search Report received in European Application No. 09004690.5 of May 11, 2009 in 7 pages. |
Marco, J. et al., Current Approach for Stenting Bifurcation Lesions, Thierry Lefevre, Yves Louvard, Marie-Claude Morice, The Paris Course on Revascularization 2004; 129-54. |
Japanese Office Action from JP application 2004-531092 dated May 6, 2010. |
Japanese Office Action from JP application 2007-176471 dated May 11, 2010. |
Canadian Office Acton from CA application 2,505,137 dated Jul. 7, 2010. |
Canadian Office Acton from CA application 2,495,234 dated May 17, 2010. |
Abizaid et al., “One-Year Follow-up After Intravascular Ultrasound Assessment of Moderate Left Main Coronary Artery Disease in Patients with Ambiguous Angiograms”, JACC vol. 34, No. 3 , pp. 707-715 (1999). |
Keeley et al., “Immediate and Long-Term Results of Elective and Emergent Percutaneous Interventions on 5 Protected and Unprotected Severaly Narrowed Left Main Coronary Arteries”, JAAC vol. 83, pp. 242-246 (1999). |
Maehara et al., Intravascular Ultrasound Assessment of the Stenoses Location and Morphology in the Left Main Coronary Artery in Relation to Anatomic Left Main Length, JAAC vol. 88, Jul. 1, 2001; pp. 1-4, © 2001 by Excerpta Medica, Inc. |
Nayak et al., “Left Main Coronary Artery Rotation Atherectomy and Stenting”, Southern Medical Journal, vol. 93, No. 4, pp. 415-423 (Apr. 2000). |
Park et al., “Stenting of Unprotected Left Main Coronary Artery Stenoses: Immediate and Late Outcomes”, JAAC vol. 31, No. 1, pp. 37-42 (Jan. 1998). |
Tan et al., “Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization 9 in 279 Patients”, Circulation, vol. 104, pp. 1609-1614 (2001). |
Office Action from U.S. Appl. No. 10/292,385, filed Nov. 11, 2002, dated Oct. 29, 2010 (7 pages). |
European Examination Report for Application No. EP 03768812.4, dated Jul. 15, 2009, in 3 pages. |
Japanese Patent Application No. 2004-531092 filed Aug. 13, 2003 Notice of Rejection Foreign Office Action of Jul. 28, 2009 in 2 pages. |
Japanese Patent Application No. 2004-551962 filed Nov. 10, 2003 Notice of Rejection Foreign Office Action of Aug. 26, 2009 in 2 pages. |
Canadian Patent Application No. 2,505,073 filed Nov. 10, 2003 Foreign Office Action of Aug. 17, 2009 in 2 pages. |
Canadian Patent Application No. 2,495,234 filed Aug. 13, 2003 Foreign Office Action of Aug. 18, 2009 in 3 pages. |
Japanese Patent Application No. 2004-548704, Decision of Rejection mailed Jan. 13, 2010, in 2 pages. |
Yachia Daniel, editor. “Stenting the Urinary System,” Isis Medical Media, Ltd., Oxford; 1998. |
Number | Date | Country | |
---|---|---|---|
20080046064 A1 | Feb 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10225484 | Aug 2002 | US |
Child | 11767422 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09580597 | May 2000 | US |
Child | 10225484 | US | |
Parent | 09011214 | US | |
Child | 09580597 | US |